February 16, 2012
The Pharmaceutical Affairs and Food Sanitation Council (PAFSC)’s Second Committee on New Drugs will discuss marketing authorization for Pfizer Japan’s Xalkori Capsule 200 mg/250 mg (crizotinib) for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)...read more